Dr. Robert S. Schwartz
Interventional Cardiologist & Inventor
Co-Founder of CorFlow Therapeutics AG, Medical Director of Education,
Minnesota Cardiovascular Research Institute and Senior Consulting Cardiologist,
Minneapolis Heart Institute, Minneapolis, MN, USA
Rob is a practising interventional cardiologist and a prolific
inventor who over the last decades has been granted numerous medical device patents.
He has been instrumental to found companies such as Osprey Medical and Autonomix and has a passion
to solve the no-reflow problem for acute heart attack patients.
Prof. Martin T. Rothman
Cardiologist & VP Medical Affairs Medtronic
Co-Founder of CorFlow Therapeutics AG, Chief Medical
Officer and VP of Medical Affairs, Medtronic Coronary, RDN
& Structural Heart, Santa Rosa, CA, USA, Honorary Professor
of Interventional Cardiology, Queen Mary, University of London, United Kingdom
Martin is a world-renown and NHS pioneer in interventional cardiology and
has founded numerous cardiology medical device companies raising more than
£300M for these early stage companies. He joined Medtronic in 2010 and is
now responsible for a wide product spectrum from coronary&vascular disease to resistant
hypertension and minimally invasive heart valves.
Gunnar M. Páh
Gunnar has over 40 year’s experience in medical device distribution, start-ups and financing.
He started as a sales manager in Medico (Oslo, Norway) and has founded successful distribution
companies in Europe (Medi-Stim AS (1984), CardioMed GmbH (1994) and MicroMed (1994)).
Gunnar is an active early stage investor in several breakthrough interventional
cardiology companies of which many have had a successful exit: AVE, Vascular Science,
Atritech, Embolic Protection, Rubicon, Sapheon, Loma Vista, CoreValve and CardiAQ.
Erik is the chairman and founder of NeoMed Management and was previously the chairman and controlling
shareholder of NeoMed AS, providing investment advisory services, specializing in small and medium sized
companies in the pharmaceutical, medical device and diagnostic industries. Erik has served as a board member
of a. o. Clavis Pharma AS (which went public on the Oslo Stock Exchange), GenoVision AS (sold to Qiagen),
Thommen Medical AG (investment sold in a private secondary sale) and Vessix Vascular Inc. (sold to Boston Scientific
Corporation), and currently serves on the Board of Directors of Axonics Modulation Technologies Inc. (USA), JenaValve
Technology Inc. (USA, Germany), Sequana Medical AG (Switzerland) and Sonendo Inc. (USA). Erik is a founder and former
chairman of the Norwegian Venture Capital Association. He holds a Dr. Scient. degree in organic chemistry from the University
of Oslo and a Master of Science degree in Management from the Graduate School of Business, Stanford University, USA.
In addition to his role as Chief Financial Officer, Tim is currently serving as the company’s interim Chairman of the Board of Directors.
Tim joined CorFlow in 2018 with 30 years’ experience in financial leadership roles. He started his career at Deloitte in Columbus, Ohio (USA).
After nine years as a practicing CPA, he went on to serve as Finance Director and CFO for a number of international companies in the United States and Europe.
Besides accounting and finance, Tim has extensive experience in business combinations, stock exchange regulations, and corporate governance. Tim holds a degree in Business Administration from The Ohio State University.